Filter posts

Legislative Hopes, Fears

Biotechnology advances are poised now more than ever to help policymakers achieve their goals of …

Approving Drugs for Alzheimer’s Disease

BIOtechNOW delves into the current state of Alzheimer’s disease research with today’s feature on regulatory …

Orphan Drugs: Making Rare Diseases Rarer

A panel at the BIO CEO & Investor Conference provided an analysis of the thriving …

Simpson Bowles Keynote to Address Debt, Taxes, Government Services and Politics

I was recently asked what the single biggest threat to the biotechnology industry is today.  …

California Biomedical Companies Cite Lack Of Funding As Major Concern

As I have mentioned in past blog posts, the U.S. bioscience industry has demonstrated stability …

FDASIA: A Step Forward for Patients

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act …

Public Health at Risk: Don’t Cut Programs that Work

In order to avoid the “fiscal cliff,” the Congress must compromise and protect our economic …

"When Genetic Engineering Came Of Age"

October 29 was the 30th anniversary of the approval by the Food and Drug Administration …

BIO Investor Forum - Raring to Go: The Race to Treat Ultra-Rare Diseases

The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering …

“Approval of Foods from Genetically Modified Animals is Unjustifiably Slow”

The Los Angeles Times reported on concerns within the U.S. animal biotech industry and the …